Accepted for Publication: October 31, 2022.
Published Online: December 29, 2022. doi:10.1001/jamaoto.2022.4264
Corresponding Author: Darrion L. Mitchell, MD, PhD, Department of Radiation Oncology, College of Medicine, The Ohio State University Wexner Medical Center, The James Cancer Hospital and Solove Research Institute, 460 W 10th Ave, Columbus, OH 43210 (darrion.mitchell@osumc.edu).
Conflict of Interest Disclosures: Dr Wieland reported a patent pending for HPV-E2 as a potential immunological target in HPV-positive cancers and its uses in managing abnormal epithelial cell growth, and a patent pending for T-cell receptors of human HPV proteins, compositions, and uses (US patent application No., 16/971, 627) filed by Emory University. No other disclosures were reported.